1300. PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS AND COINFECTION IN A POPULATION-BASED SAMPLE OF WOMEN ATTENDING CERVICAL CANCER SCREENING IN NEW MEXICO, USA
Session: Poster Abstract Session: Clinical Infectious Diseases: Sexually Transmitted Infections
Friday, October 28, 2016
Room: Poster Hall
Posters
  • STI prevalence.pdf (2.4 MB)
  • Background: Comprehensive unbiased estimates of the prevalence of sexually transmitted infections and co-infections are critical to monitor the impact of STI prevention and control programs

    Methods: We conducted a population-based surveillance of sexually transmitted infections using an age and cervical cytology stratified random sample of 6,619 liquid-based cytology specimens collected during routine cervical cancer screening in New Mexico from 8/1/13 to 7/31/14. The New Mexico HPV Pap Registry (NMHPVPR) which collects state-wide data for all HPV tests as Notifiable Diseases and Conditions was used as the data source to define the sample selection. Chlamydia trachomatis (CT), Neisseria gonorrhea (GC), Mycoplasma genitalium (Mgen), Trichomonas vaginalis, and high-risk human papillomavirus (HR-HPV) infections were assessed using standard nucleic acid amplification (APTIMA, Hologic). Prevalence estimates and 95% CI were corrected for sampling design using the survey command in STATA v13

    Results: Prevalence among women aged 21-64 years (recommended cervical cancer screening age) was 9.4% (8.7-10.1) HR-HPV, 1.9% (1.6-2.3) CT, 3.3% (2.8-3.8trichomonas, 1.9% (1.6-2.3) Mgen, and 0.10% (0.05-0.23) GCSTI prevalence was highest in 21-24 years, declining continuously through age, although trichomonasremained high through 39 yearsDespite similar marginal prevalence of CT and Mgenin the 21-30 year old women, co-infection was relatively uncommon (15.3% of CT positives co-infected with Mgen and 12.6% of Mgen positives co-infected with CT).Although co-infections are rare they are statistically higher than would be expected assuming independence, in all but HR-HPV and trichomonas co-infections.

     

    HR-HPV

    CT

    Trichomonas

    Mgen

    21-30

    17.9 (16.6-19.4)

    4.4 (3.6-5.3)

    4.2 (3.4-5.1)

    4.6 (3.8-5.5)

    31-39

    10.6 (8.8-12.6)

    1.7 (1.0-2.9)

    4.8 (3.5-6.5)

    2.0 (1.3-3.2)

    40-64

    4.5 (3.7-5.4)

    0.7 (0.4-1.2)

    2.1 (1.6-2.9)

    0.5 (0.3-0.9)


    Conclusion:  This strategy for a population-based estimation of STI infection and co-infection prevalence will provide a useful tool for unbiased surveillance and control in the state of New Mexico. Understanding co-infection rates and the high rate of trichomonas infection through age 40 years warrants further investigation.

    Patti Gravitt, PhD1, Nicole Patterson, Associate Scientist1, Emma Stanislawski, MPH1, Elizabeth Colquitt, Statistician2, Scott Norville, MD3, Jack Cuzick, PhD2 and Cosette M. Wheeler, PhD4, (1)University of New Mexico, Albuquerque, NM, (2)Queen Mary’s University, London, UK, Albuquerque, NM, (3)Internal Medicine, University of New Mexico, Albuquerque, NM, (4)Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM

    Disclosures:

    P. Gravitt, Hologic: Received research reagents for study at no cost , Research support

    N. Patterson, None

    E. Stanislawski, None

    E. Colquitt, None

    S. Norville, None

    J. Cuzick, Qiagen: Grant Investigator , Research support
    BD: Investigator and Speaker's Bureau , Research support
    Abbott: Investigator and Speaker's Bureau , Research support and Speaker honorarium
    Hologic: Investigator and Speaker's Bureau , Research support and Speaker honorarium
    Trovagene: Investigator and Speaker's Bureau , Research support and Speaker honorarium
    Genera: Investigator and Speaker's Bureau , Research support and Speaker honorarium
    Cepheid: Investigator and Speaker's Bureau , Research support and Speaker honorarium
    Merck: Consultant , Speaker honorarium

    C. M. Wheeler, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.